http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108125921-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2806 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28 |
| filingDate | 2017-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108125921-B |
| titleOfInvention | Posaconazole solid dispersion composition capable of inhibiting crystallization and preparation method thereof |
| abstract | The invention discloses a posaconazole solid dispersion composition capable of inhibiting crystallization and a preparation method thereof, and relates to the field of posaconazole preparations. The research of the invention finds that compared with hydroxypropyl methylcellulose acetate succinate (HPMCAS) as a carrier material, the posaconazole solid dispersion composition adopts the acrylic resin as the carrier material, and after posaconazole seed crystal is added in a pH6.8 dissolution test simulating an intestinal environment for induction, the posaconazole solid dispersion composition has stronger crystallization inhibition capability, and can enable the medicine to have better in-vivo absorption. |
| priorityDate | 2017-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 33.